ArcheMedX Bolsters Team, Appoints Kelly Ritch as Vice President Clinical Research Solutions

by Joel Selzer Nov 14 , 2019 5 min read

Kelly Ritch’s addition better equips ArcheMedX to scale the capabilities it provides to transform clinical operations.

Charlottesville, VA (PRWEB) November 14, 2019

 ArcheMedX, the company improving clinical trial readiness, today announced the expansion of its senior leadership team. To support increasing demand for Ready, the company’s clinical trials platform, with sponsors and CROs, ArcheMedX has appointed Kelly Ritch as Vice President of Clinical Research Solutions. Kelly will apply her 20 years of clinical operations experience to accelerate growth of the company’s clinical research business.

“As the complexity and cost of clinical research increases, a key to reducing the risk of under-performing trials is ensuring the preparedness of staff and sites” said Ms. Ritch. She added, “I’m excited to join the ArcheMedX team and help clinical operations leaders make faster, more informed decisions that improve trial efficiency and outcomes.”

Kelly is a dynamic and innovative executive adept at driving high-performance and long-term value through the applied use of software, data, and technology driven solutions for clinical research. Her operational expertise and strategic mindset will enable ArcheMedX to scale the capabilities it provides to a growing customer base.

Nearly every clinical trial encounters operational challenges and according to industry reports 86% of trials experience a study startup delay and 72% of studies run more than one month behind schedule. These delays can have significant financial costs for each day that a trial impedes a product’s development and launch.

New call-to-action

 

At ArcheMedX, we arm trial stakeholders with more than an advanced training solution —  we provide the early warning detection they need to mitigate operational risk and reduce costly delays,” said ArcheMedX CEO and co-founder Joel Selzer. “This is a pivotal time for the clinical research sector, and we are thrilled to have an industry leader with Kelly’s breadth of experience join the team. With Kelly’s appointment we are better equipped to expand the product and commercial strategies at ArcheMedX that will transform clinical operations.”

Kelly has previously led clinical data management, sales and marketing, clinical trial operations, and strategic partnerships with both sponsors and CROs.  While creating and leading high-performance teams across clinical research functions, Kelly has had the opportunity to evaluate, implement, and develop a number of key software platforms used to support and improve clinical trial performance. Kelly has earned degrees from University of Virginia, University of North Carolina Chapel Hill, and University of Virginia Darden School of Business.

About ArcheMedX

ArcheMedX applies behavioral science to transform learning and generate actionable insights across the life sciences and healthcare industries. Ready, the company’s clinical trial readiness platform, enables clinical research leaders to evaluate and improve the preparedness of project teams and site personnel and serves as an early warning detection system to reduce the risks and costs associated with under-performing clinical trials. To learn more about our operational intelligence and workforce readiness solutions visit www.archemedx.com or follow ArcheMedX on LinkedIn.

New call-to-action

Related Post

20 min Read 9 Sep, 2020

Choosing a Solution to Train Clinical Trial Site Staff Virtually? Start With this Checklist.

Choosing the right way to train clinical trial staff is complex and exhausting under normal…

Molly Bryant
Molly Bryant
15 min Read 9 Sep, 2020

The Virtual Clinical Trial Start-Up: How to Make It Work

Making it through the clinical trial start-up process is critical for any study - and…

Molly Bryant
Molly Bryant
12 min Read 1 Sep, 2020

Survey Reveals that Study Start-Up is the Latest Target in the March to Virtual Clinical Trials

As clinical trials ground to a halt in Q1 of this year, no one knew…

Molly Bryant
Molly Bryant